Biogen Seeks Tysabri Magic TOUCH Again: REMS Allows Rapid PML Response

Biogen Idec developed TOUCH, the restricted distribution risk management plan for its monoclonal antibody Tysabri (natalizumab), to save that product from market withdrawal in 2005-2006